New drug plus immunotherapy after surgery for non-small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether giving an experimental drug (SYS6010) together with an immunotherapy (a type of treatment that helps your immune system fight cancer) after surgery can lower the chance of cancer coming back. It's for people with non-small cell lung cancer that was completely removed but didn't respond very well to surgery alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (the most common type of lung cancer).
- You are between 18 and 75 years old.
- You have already had surgery to completely remove the cancer, with clean margins (no cancer left at the edges).
- Your cancer is at stage II, IIIA, or early IIIB (it hasn't spread far).
- Your tumor does not have certain genetic changes that already have targeted treatments.
- After surgery, your cancer did not shrink enough to be considered mostly gone.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that combines a drug called SYS6010 with an immunotherapy (Enlonstobart) compared to the usual immunotherapy plus chemo for advanced lung cancer. The goal is to see if this combo works better and helps people with PD-L1 positive lung cancer live longer and feel better.
This trial tests whether giving more immunotherapy after surgery can help people with non-small cell lung cancer who still had some cancer cells left after their first round of immunotherapy and chemotherapy before surgery. It aims to improve outcomes for those whose tumor didn't fully disappear.
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
This trial tests whether giving two immunotherapy drugs before surgery can help shrink non-small cell lung cancer and improve treatment success. The drugs are toripalimab and sacituzumab tirumotecan, which are given as intravenous infusions.
This trial tests whether giving a type of immunotherapy (sintilimab) along with chemotherapy before and after surgery to remove the main lung tumor can help people with advanced non-small cell lung cancer. The goal is to see if this approach improves outcomes compared to standard treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.